6DECEMBER - 2022TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comChina's pharmaceutical industry has switched from focusing solely on creating generic drugs to creating more innovative drugs driven by new and complex clinical needs, rapid market expansion, and regulatory system reform. The Chinese pharmaceutical policy has historically been fragmented and uncoordinated between provinces. But this is set to change as the nation restructures the sector and enhances its capacity to compete globally while still ensuring that the advantages of the expansion are passed on to domestic patients.While the Chinese pharmaceutical market continues to face uncertainty on the back of challenges around drug pricing and low levels of intellectual property protection, the country still presents one of the most attractive investment destinations in the APAC region. The immense growth of China's healthcare industry has allowed it to begin the transition from being a pharmaceutical manufacturing base to a strategic R&D hub, cementing itself as a strategic player in the global pharmaceutical market, both as a consumer country and as a platform for establishing greater R&D. In this edition of Pharma Tech Outlook APAC, we present some of the most promising companies in the Pharma Tech space in China. The issue features thought leadership articles from Alexander Bernikov, Medical Director, Clinical Development (Uro)-Oncology, Jiangsu Hengrui Pharmaceuticals, Nick Thomson, Senior Director, Chemical Research and Development, Pfizer Inc, Carlos Pedraza, Ph.D. Director of CNS Biology, Alkermes, Federico Piutti, Innovation Manager, Bormioli Pharma, and Philippe Caby, CIO, Centrient Pharmaceuticals. The edition also showcases innovative solutions from SHANHU, a renowned clinical trial and research management company that provides cloud-based digital intelligence platforms. SHANHU's solutions are powered by industry-leading intelligent (brain-like) engines and cover the gamut of closed-loop drug supply management.Leafing through these pages will give you comprehensive insights into the innovative trends and latest developments in the Pharma Tech landscape.The Resurgence of the Chinese Pharma Tech IndustryCopyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.DECEMBER - 2022, Vol 08 - Issue 21 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Disclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsEditor-in-ChiefStacey SmithVisualizerRonald DonovanMichael WayneEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:TECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >